BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+0.5%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.7B
AUM Growth
+$9.7B
(-1.5%)
Cap. Flow
+$400M
Cap. Flow
% of AUM
4.13%
Top 10 Holdings %
Top 10 Hldgs %
29.73%
Holding
233
New
14
Increased
61
Reduced
63
Closed
42
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$137M |
| 2 |
CareDx
CDNA
|
$65.3M |
| 3 |
Abbott
ABT
|
$50.4M |
| 4 |
Molina Healthcare
MOH
|
$46.5M |
| 5 |
Danaher
DHR
|
$44.5M |
Top Sells
| 1 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$63.1M |
| 2 |
Centene
CNC
|
$40.7M |
| 3 |
Baxter International
BAX
|
$40.6M |
| 4 |
Hologic
HOLX
|
$22.3M |
| 5 |
DexCom
DXCM
|
$15.4M |
Sector Composition
| 1 | Healthcare | 97.85% |
| 2 | Technology | 0.8% |
| 3 | Industrials | 0.75% |
| 4 | Communication Services | 0.02% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.37B
| $434M | 4.47% | 1,709,249 -18,100 | -1% | -$4.6M |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $393M | 4.06% | 1,791,761 +30,145 | +2% | +$6.62M |
|
3
argenx
ARGX
$43.6B
| $349M | 3.6% | 997,038 +13,100 | +1% | +$4.59M |
|
4
Ionis Pharmaceuticals
IONS
$6.8B
| $315M | 3.25% | 10,355,123 +1,007,197 | +11% | +$30.6M |
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $271M | 2.79% | 3,180,551 +176,500 | +6% | +$15M |
|
|
6
Abbott
ABT
$231B
| $246M | 2.53% | 1,745,801 +358,302 | +26% | +$50.4M |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $226M | 2.33% | 1,335,140 -73,278 | -5% | -$12.4M |
|
8
Fate Therapeutics
FATE
$120M
| $221M | 2.28% | 3,775,736 +537,700 | +17% | +$31.5M |
|
9
Incyte
INCY
$16.5B
| $217M | 2.24% | 2,957,000 | – | – |
|
10
Elevance Health
ELV
$71.8B
| $211M | 2.18% | 455,294 -19,916 | -4% | -$9.23M |
|
|
11
Intuitive Surgical
ISRG
$170B
| $210M | 2.16% | 584,463 +380,868 | +187% | +$137M |
|
|
12
Danaher
DHR
$147B
| $195M | 2.01% | 591,800 +135,121 | +30% | +$44.5M |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $190M | 1.96% | 3,628,919 -145,000 | -4% | -$7.59M |
|
14
Arvinas
ARVN
$568M
| $183M | 1.89% | 2,233,403 -8,000 | -0.4% | -$657K |
|
15
UnitedHealth
UNH
$281B
| $157M | 1.62% | 312,281 -25,701 | -8% | -$12.9M |
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $143M | 1.47% | 4,349,292 +7,300 | +0.2% | +$240K |
|
17
Tandem Diabetes Care
TNDM
$845M
| $143M | 1.47% | 949,257 -85,262 | -8% | -$12.8M |
|
18
Humana
HUM
$36.5B
| $141M | 1.45% | 303,697 -9,065 | -3% | -$4.2M |
|
19
MacroGenics
MGNX
$112M
| $137M | 1.42% | 8,560,462 +15,865 | +0.2% | +$255K |
|
|
SAGE
20
DELISTED
Sage Therapeutics
SAGE
| $137M | 1.42% | 3,228,004 +19,000 | +0.6% | +$808K |
|
|
21
DexCom
DXCM
$29.5B
| $126M | 1.3% | 235,153 -28,686 | -11% | -$15.4M |
|
22
Relay Therapeutics
RLAY
$619M
| $126M | 1.3% | 4,105,962 +350,000 | +9% | +$10.7M |
|
23
Biogen
BIIB
$19.4B
| $126M | 1.3% | 525,000 -2,000 | -0.4% | -$480K |
|
24
Boston Scientific
BSX
$156B
| $126M | 1.3% | 2,964,031 -3,096 | -0.1% | -$132K |
|
25
Edwards Lifesciences
EW
$47.8B
| $119M | 1.23% | 921,185 +51,234 | +6% | +$6.64M |
|